Weight loss of 510% of initial body weightcommonly achieved with Saxendais associated with meaningful reductions in both systolic and diastolic blood pressure
Pantanetti P, Cangelosi G, Alberti S, Di Marco S, Michetti G, Cerasoli G, et al
However, each new dose increase temporarily floods your system with higher hormone levels
This is not a self-administration peptide
Along with preclinical data indicating that long-acting GIPR agonists act in the brain to decrease body weight and food intake via GIPR signalling in inhibitory -aminobutyric acid-producing (GABAergic) neurons 5,6,7 , and by mitigating the emetic effects of GLP-1R agonism 8,9 , GIPRGLP-1R co-agonism has been established as a highly effective strategy for the management of obesity, type 2 diabetes and MASH
The development of patient assistance programs and structured payment options is improving treatment affordability for middle-income populations